AZGP1 inhibits soft tissue sarcoma cells invasion and migration

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Identifying metastasis predictors in soft tissue sarcomas is a significant clinical challenge.
• Alpha-2-glycoprotein 1 (AZGP1) is a potential cancer progression biomarker, but its role in soft tissue sarcomas is unestablished.
• This study investigates AZGP1 expression and its association with tumor progression in soft tissue sarcomas.

Purpose of the Study:

• To determine AZGP1 expression levels in soft tissue sarcomas.
• To analyze the correlation between AZGP1 expression and tumor progression, including metastasis and survival.
• To explore the functional impact of AZGP1 on cancer cell migration and invasion in vitro.

Main Methods:

• Quantitative RT-PCR and immunohistochemistry (IHC) were used to assess AZGP1 expression in 86 soft tissue sarcoma patient samples.
• Clinicopathological features were analyzed in relation to AZGP1 levels.
• In vitro studies utilized fibrosarcoma, rhabdomyosarcoma, and synovial sarcoma cell lines with lentiviral over-expression and knockdown assays to evaluate AZGP1's effect on cellular migration and invasion.

Main Results:

• AZGP1 expression negatively correlated with metastasis and overall survival in soft tissue sarcomas (p < 0.05).
• Lower AZGP1 expression was observed in patients with metastasis compared to those without.
• Kaplan-Meier analysis indicated shorter overall (p=0.056) and metastasis-free survivals (p=0.038) in patients with low AZGP1 expression.
• In vitro, AZGP1 over-expression reduced cell migration and invasion, while AZGP1 knockdown enhanced these processes.

Conclusions:

• Reduced AZGP1 expression is associated with increased in vitro cellular migration and invasion.
• Lower AZGP1 levels in soft tissue sarcomas correlate with a higher risk of metastasis and reduced patient survival.
• AZGP1 may serve as a valuable prognostic biomarker for soft tissue sarcomas.